2026 ICD-10-CM Diagnosis Code D86.84Sarcoid pyelonephritis

ICD-10-CM Codes›D50–D89›D80-D89›D86

ICD-10-CM D86.84
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D86.84 is a billable ICD-10-CM diagnosis code for sarcoid pyelonephritis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 196 through 198. Coders also document this condition as granulomatous sarcoid nephropathy. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Immunity disorders.

Code Identity

ICD-10-CM Code
D86.84
Billable Status
Yes — Valid for Submission
Code Describes
Sarcoid pyelonephritis
Short Description
Sarcoid pyelonephritis
Same as the full description in the CMS dataset.
Parent Code
D86.8
Sarcoidosis of other sites

Code Classification

ChapterD50–D89Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
SectionD80-D89Certain disorders involving the immune mechanism
CategoryD86Sarcoidosis
This CodeD86.84Sarcoid pyelonephritis

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Granulomatous sarcoid nephropathy
  • Granulomatous tubulointerstitial nephritis

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Tubulo-interstitial nephropathy in sarcoidosis

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Disorder(of)
      • tubulo-interstitial (in)
        • sarcoidosis
    • Pyelonephritis
      • in (due to)
        • sarcoidosis
    • Sarcoid
      • pyelonephritis
    • Sarcoidosis
      • with
        • tubulo-interstitial nephropathy

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR BLD008
Immunity disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Sarcoidosis

Sarcoidosis is a condition in which groups of cells in your immune system form small, red, and swollen (inflamed) lumps. These lumps are called granulomas. They can form in any organ in the body. But they most commonly affect the lungs and lymph nodes in the chest. Over time, sarcoidosis can cause permanent scarring of organs.

The full article covers:

  • What is sarcoidosis?
  • What causes sarcoidosis?
  • Who is more likely to develop sarcoidosis?
  • What are the symptoms of sarcoidosis?
  • What other problems can sarcoidosis cause?
  • How is sarcoidosis diagnosed?
  • What are the treatments for sarcoidosis?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D86.84 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
135 Sarcoidosis
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D86.84Overview

Is D86.84 (Sarcoidosis of other sites) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report sarcoid pyelonephritis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D86.84 group to?

When sarcoid pyelonephritis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 196, 197, 198, with relative weights from 0.7162 to 1.8872 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D86.84?

Under the General Equivalence Mappings, sarcoid pyelonephritis converts to ICD-9-CM 135 (sarcoidosis). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.